CN119403544A - 新型脂质纳米颗粒组合物及其用途 - Google Patents

新型脂质纳米颗粒组合物及其用途 Download PDF

Info

Publication number
CN119403544A
CN119403544A CN202380047304.0A CN202380047304A CN119403544A CN 119403544 A CN119403544 A CN 119403544A CN 202380047304 A CN202380047304 A CN 202380047304A CN 119403544 A CN119403544 A CN 119403544A
Authority
CN
China
Prior art keywords
lipid
composition
ganglioside
cells
lipids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380047304.0A
Other languages
English (en)
Chinese (zh)
Inventor
吴斌
宋鹤梁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Satodam Corp
Original Assignee
Satodam Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Satodam Corp filed Critical Satodam Corp
Publication of CN119403544A publication Critical patent/CN119403544A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202380047304.0A 2022-06-29 2023-06-29 新型脂质纳米颗粒组合物及其用途 Pending CN119403544A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263356557P 2022-06-29 2022-06-29
US63/356,557 2022-06-29
PCT/US2023/026541 WO2024006414A1 (en) 2022-06-29 2023-06-29 Have been novel lipid nanoparticle compositions and uses thereof

Publications (1)

Publication Number Publication Date
CN119403544A true CN119403544A (zh) 2025-02-07

Family

ID=89381439

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380047304.0A Pending CN119403544A (zh) 2022-06-29 2023-06-29 新型脂质纳米颗粒组合物及其用途

Country Status (6)

Country Link
US (2) US12303569B2 (OSRAM)
EP (1) EP4547224A1 (OSRAM)
JP (1) JP2025525308A (OSRAM)
CN (1) CN119403544A (OSRAM)
AU (1) AU2023297939A1 (OSRAM)
WO (1) WO2024006414A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120948302A (zh) * 2024-05-13 2025-11-14 国立医药品食品卫生研究所 使用离心场流分级检测颗粒的方法
WO2025250539A1 (en) * 2024-05-29 2025-12-04 Cytodigm, Inc. Pharmaceutical composition comprising sialic acid for treating diseases related to the lung

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150291969A1 (en) * 2014-01-30 2015-10-15 Chromatin, Inc. Compositions for reduced lignin content in sorghum and improving cell wall digestibility, and methods of making the same
AU2020301161B2 (en) * 2019-06-25 2023-10-26 Gilead Sciences, Inc. FLT3L-Fc fusion proteins and methods of use
CN116568331A (zh) * 2020-10-05 2023-08-08 希托迪格姆公司 Siglec-结合剂的药物组合物

Also Published As

Publication number Publication date
AU2023297939A1 (en) 2024-11-28
JP2025525308A (ja) 2025-08-05
WO2024006414A1 (en) 2024-01-04
EP4547224A1 (en) 2025-05-07
US12303569B2 (en) 2025-05-20
WO2024006414A8 (en) 2025-02-27
US20250001003A1 (en) 2025-01-02
US20250099394A1 (en) 2025-03-27

Similar Documents

Publication Publication Date Title
JP6442551B2 (ja) 薬物送達用の脂質ナノ粒子の生成方法
US10155945B2 (en) Method of producing lipid nanoparticles for drug delivery
CN101291653B (zh) 脂质包封的干扰rna
CN1882693B (zh) 聚乙二醇修饰的脂质化合物及其应用
CA2823182C (en) Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof
US12303569B2 (en) Lipid nanoparticle compositions and uses thereof
Merkel et al. Triazine dendrimers as nonviral vectors for in vitro and in vivo RNAi: the effects of peripheral groups and core structure on biological activity
US20060051405A1 (en) Compositions for the delivery of therapeutic agents and uses thereof
ES2386549T3 (es) Composición para inhibir la expresión de un gen diana
US9730893B2 (en) Lipid assemblies comprising anionic lysolipids and use thereof
CN1981044A (zh) 包封干扰rna的脂质
CN120957708A (zh) 用于反义寡核苷酸递送的脂质纳米粒制剂
US20260000627A1 (en) Novel lipid nanoparticle compositions and uses thereof
CN117534585A (zh) 一种新型可电离阳离子脂质化合物及其制备方法与应用
EP4563142A1 (en) Lipid nanoparticle and pharmaceutical composition
WO2026036007A1 (en) Novel lipid nanoparticle compositions and uses thereof for treating diseases in bone marrow
CN121796628A (zh) 一种靶向脂质纳米颗粒及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Wu Bin

Inventor after: Song Heliang

Inventor after: victoria. TRENTO

Inventor before: Wu Bin

Inventor before: Song Heliang

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination